CVE-2021-29868

CVE-2021-29868 is a medium-severity vulnerability in Ibm I2 Ibase with a CVSS 3.x base score of 5.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-613.

Key facts

Description

IBM i2 iBase 8.9.13 and 9.0.0 could allow a local attacker to obtain sensitive information due to insufficient session expiration. IBM X-Force ID: 206213.

Frequently asked questions

What is CVE-2021-29868?
IBM i2 iBase 8.9.13 and 9.0.0 could allow a local attacker to obtain sensitive information due to insufficient session expiration. IBM X-Force ID: 206213.
How severe is CVE-2021-29868?
CVE-2021-29868 has a CVSS 3.x base score of 5.5, rated medium severity. It is exploitable over local access with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2021-29868 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 0% (11th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2021-29868?
CVE-2021-29868 primarily affects Ibm I2 Ibase. In total, 2 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.
How do I fix CVE-2021-29868?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2021-29868 published?
CVE-2021-29868 was published on 2021-10-27 and last updated on 2026-06-17.

References

Affected products (2)

More vulnerabilities in Ibm I2 Ibase

All CVEs affecting Ibm I2 Ibase →

Other CWE-613 (Insufficient Session Expiration) vulnerabilities

Browse all CWE-613 (Insufficient Session Expiration) vulnerabilities →